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A B S T R A C T
The adenosine 2A receptor (A2AR), a G-protein-coupled receptor (GPCR), was solubilised and purified en-
capsulated in styrene maleic acid lipid particles (SMALPs). The purified A2AR-SMALP was associated with
phospholipids characteristic of the plasma membrane of Pichia pastoris, the host used for its expression, con-
firming that the A2AR-SMALP encapsulated native lipids. The fluorescence spectrum of the A2AR-SMALP showed
a characteristic broad emission peak at 330 nm, produced by endogenous Trp residues. The inverse agonist
ZM241385 caused 30% increase in fluorescence emission, unusually accompanied by a red-shift in the emission
wavelength. The emission spectrum also showed sub-peaks at 321 nm, 335 nm and 350 nm, indicating that
individual Trp inhabited different environments following ZM241385 addition. There was no effect of the
agonist NECA on the A2AR-SMALP fluorescence spectrum. Substitution of two Trp residues by Tyr suggested that
ZM241385 affected the environment and mobility of Trp2466.48 in TM6 and Trp2687.33 at the extracellular face
of TM7, causing transition to a more hydrophobic environment. The fluorescent moiety IAEDANS was site-
specifically introduced at the intracellular end of TM6 (residue 2316.33) to report on the dynamic cytoplasmic
face of the A2AR. The inverse agonist ZM241385 caused a concentration-dependent increase in fluorescence
emission as the IAEDANS moved to a more hydrophobic environment, consistent with closing the G-protein
binding crevice. NECA generated only 30% of the effect of ZM241385. This study provides insight into the
SMALP environment; encapsulation supported constitutive activity of the A2AR and ZM241385-induced con-
formational transitions but the agonist NECA generated only small effects.
1. Introduction
G-protein-coupled receptors (GPCRs) are the largest class of mem-
brane proteins in the human genome (with>800 receptors) and are
central to drug discovery programs as they are the therapeutic target for
30–40% of clinically-prescribed drugs [1]. They share a common ar-
chitecture comprising a bundle of seven transmembrane helices (TMs)
[2]. The structural biology of GPCRs is now well established, with
crystal structures for> 50 different GPCRs currently deposited and
over 250 of their complexes with different ligands [3]. This structural
information is now being enhanced further by cryo-EM structures of
GPCR complexes [4,5]. This extensive structural information has
highlighted that GPCRs are highly dynamic proteins and that the re-
ceptor conformation is dictated by the structure and efficacy of the
bound ligand (full agonist, partial agonist, antagonist or inverse agonist
– which inhibits basal signalling). This spectrum of conformations
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allows these receptors to couple to multiple effectors [6] and for re-
sponses to be ‘tuned’, up or down, by allosteric modulators that bind to
sites discrete from the orthosteric site used by the natural agonist [7].
This structural knowledge-base has facilitated an understanding of the
conserved conformational changes that underpin GPCR activation in
general [8]. Nevertheless, it is now recognised that approaches are
required that progress beyond static structures to a dynamic under-
standing. Although solution-based NMR spectroscopy of GPCRs in de-
tergent micelles is starting to address aspects of this [9], it is ac-
knowledged that GPCRs need to be studied in an environment closer to
their physiological context within the lipid bilayer of a cell membrane.
This is particularly important for investigating GPCRs as they are
regulated by the juxtaposition of specific membrane lipids [10–12].
In recent years there has been a growing interest in the use of
membrane mimetic systems for studying membrane proteins. The use of
poly(styrene-co-maleic acid) (SMA) has increasingly been adopted as a
strategy for extracting a nanoscale disc of native cell membrane bilayer
encapsulated by the SMA polymer, referred to as SMA lipid particle
(SMALP) [13–16]. SMA has its limitations in some downstream biolo-
gical applications. In particular, SMALPs have been shown to be un-
stable in the presence of divalent cations such as Mg2+, with pre-
cipitation of the polymer evident at 5 mM Mg2+. SMA is also pH
sensitive. In an acidic environment (pH values< 5.8), the maleic acid
groups become protonated causing the polymer to precipitate. This
limits the SMALP approach to proteins that function at neutral or basic
pHs [17]. Nevertheless, SMALPs have attracted considerable interest for
purifying membrane proteins including GPCRs.
We reported the first purification of an active GPCR, in the complete
absence of detergent at any stage using the SMALP approach [18,19];
other GPCRs have subsequently been solubilised [20]. The first GPCR-
SMALP purified was the the adenosine A2A receptor (A2AR). This is a
typical GPCR with a well-defined pharmacology. It belongs to a family
of four GPCRs (A1R, A2AR, A2BR, A3R) that mediate the actions of
adenosine and are attractive drug targets [21]. The A2AR regulates
blood flow to cardiac muscle and regulates the release of the neuro-
transmitters dopamine and glutamate in the brain, and is well-known as
the target for caffeine, which blocks this receptor [22]. It is noteworthy
that the A2AR has been shown to possess basal activity in the absence of
agonist stimulation, referred to as constitutive activity [23]. This re-
ceptor is a good choice as a model receptor to investigate the structure/
function of a GPCR as there is a wealth of structural information for the
A2AR with over 40 structures deposited in the Protein Data Bank as
listed in the GPCRdb [3]. This includes the conformation of the A2AR
bound to ligands of different efficacy (full agonist, partial agonist, an-
tagonist, inverse agonist) with corresponding structures of fully active,
partially active and inactive, receptor conformations [24].
In this study we investigate ligand-induced conformational changes
to the A2AR encapsulated in a SMALP using a combination of fluores-
cence from endogenous Trp residues plus fluorescence from an in-
troduced reporter (IAEDANS) positioned in a dynamic part of the re-
ceptor structure, at the cytoplasmic end of TM6. We establish that the
A2AR adopted at least a partially active conformation in the SMALP and
was able to undergo ligand-induced conformational change in response
to binding the inverse agonist ZM241385. In contrast, the SMALP-en-
capsulated A2AR exhibited little conformational change in response to
the full agonist NECA. This has ramifications for using GPCR-SMALPs as
a platform for studying GPCRs.
2. Materials and methods
2.1. Materials
SMA2000 anhydride was from Cray Valley (UK). ZM241385 {4-(2-
[7-amino-2-(furan-2-yl)[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl amino]
ethyl)phenol} was purchased from Tocris, The mutant constructs
[W246Y]A2AR and [W268Y]A2AR were custom synthesised and cloned
into the EcoRI-NotI sites of the vector pPICZαA by Genscript.
2.2. Human A2AR expression
An N-terminal His-tagged A2AR was expressed in Pichia pastoris as
described previously [18]. The receptor sequence terminated at Ala316
(Fig. S1) as this construct is degradation resistant [25] and has been
used extensively in structural studies, having wild-type pharmacology
[26,27]. Prior to SMA-extraction, cells were disrupted following sus-
pension in breaking buffer (50 mM sodium–phosphate buffer, 100 mM
NaCl, 5% glycerol, EDTA-free protease inhibitor, pH 7.5, 4 °C) by 3–5
passes using an Avestin Emulsiflex C3 cell-disrupter. Unbroken cells
and debris were removed by centrifugation (5000 ×g, 10 min, 4 °C).
The A2AR-expressing membrane fraction was then sedimented
(100,000 ×g, 60 min, 4 °C) and re-suspended to 80 mg ml−1 (wet
weight) in extraction buffer (300 mM NaCl, 20 mM HEPES, pH 7.5).
Membranes were stored at −80 °C until needed.
2.3. Generation of A2AR-SMALPs
SMA was prepared from SMA anhydride and used to solubilise A2AR
from membranes as described previously [16,18]. Briefly, A2AR-ex-
pressing membrane preparations were thawed on ice, and an equal
volume of 2 × SMA buffer (5% w/v SMA, 300 mM NaCl, 20 mM
HEPES, EDTA-free protease inhibitor, pH 7.5) added to yield a final
concentration of 40 mg ml−1 (wet weight) in 2.5% (w/v) SMA. Fol-
lowing gentle agitation for 1 h at room temperature, non-solubilised
material was removed by centrifugation (100,000 ×g, 60 min, 4 °C) to
yield a supernatant containing A2AR–SMALPs.
2.4. Purification of A2AR-SMALPs
All purification steps were carried out at 4 °C. The A2AR–SMALP
supernatant was incubated with ~1 ml Ni2+-NTA resin, overnight on
an end-over-end rotator. The column was washed with 20 column vo-
lumes (cv) of wash buffer (300 mM NaCl, 20 mM HEPES, 25 mM imi-
dazole, EDTA-free protease inhibitor pH 7.5). Elution of A2AR–SMALP
was achieved with 10 cv of elution buffer (300 mM NaCl, 20 mM
HEPES, 250 mM imidazole, EDTA-free protease inhibitor pH 7.5).
Elution fractions were pooled, buffer-exchanged into assay buffer
(300 mM NaCl, 20 mM HEPES, pH 7.5) and concentrated using spin-
concentrators (10 kDa cut-off). Concentrations of purified A2AR-SMALP
were determined using SDS-PAGE and densiometric analysis against
protein standards in ImageJ. Final concentrations ranged between 0.2
and 1 mg ml−1.
2.5. IAEDANS labelling
Ala2316.33 of the A2AR was mutated to Cys using the QuikChange
site-directed mutagenesis kit (Stratagene, Cambridge, UK) according to
the manufacturer's instructions. The oligonucleotide primers 5′-G-AAA-
GAG-GTT-CAC-TGT-GCT-AAG-TCC-TTG-3′ (sense) and 5′-CAA-GGA-
CTT-AGC-ACA-GTG-AAC-CTC-TTT-C-3′ (antisense) were used, with
appropriate base changes shown in bold. All receptor constructs were
confirmed by automated fluorescent sequencing. For labelling by
IAEDANS (5-({2-[(iodoacetyl)amino]ethyl}amino)naphthalene-1-sul-
fonic acid), 0.05 mg of [A231C]A2AR-SMALP in phosphate buffer
(50 mM NaH2PO4, 300 mM NaCl, pH 8.0) was added to 3 μl of 5 mM
IAEDANS in DMSO (10-fold excess of IAEDANS) in a total reaction
volume of 100 μl and incubated for 3 h at 20 °C with gentle rotation.
Samples were then prepared using a Vivaspin 500 centrifugal con-
centrator (10,000 MWCO; 15,000 ×g, 2 min), washed with 3 × 200 μl
phosphate buffer then centrifuged as above to reduce sample volume to
100 μl. Labelling of ‘empty SMALPs’ (DMPC-SMALPs) containing the
lipid DMPC but lacking A2AR was performed using the same protocol.
S.J. Routledge, et al. BBA - Biomembranes 1862 (2020) 183235
2
2.6. Fluorescence measurements
Fluorescence measurements were made using a PTI QuantaMaster
300 fluorimeter using continuous Xe arc excitation. Samples were
contained in a 0.3 cm quartz fluorescence cuvette (Starna Scientific).
Emission spectra were obtained by exciting the protein at 295 nm and
340 nm for tryptophan and IAEDANS respectively. Excitation slit
widths of 0.2 mm (± 0.8 nm) and emission slit widths of 0.8 mm
(±3.2 nm) were used for all measurements with a scan speed of
500 nm/min. Emission spectra were measured between 300 and
400 nm for tryptophan fluorescence experiments and 425–625 nm for
IAEDANS. For determination of Stern-Volmer constants, acrylamide
was titrated into the cuvette up to a final concentration of 2 M. At each
titration point the emission intensity of the tryptophan was measured.
The resulting intensity data were adjusted to take into account the ef-
fect of diluting the A2AR-SMALP, then plotted to provide a Stern-Volmer
constant using the equation F0/F−1 = 1 + κqτ0[Q], where F0 is the
intensity of fluorescence in the absence of quencher, F−1 is the intensity
with the quencher, present at concentration [Q], τ0 is the lifetime of the
excited state and κq is the Stern-Volmer constant.
2.7. Lipid extraction
Total lipid was extracted from P. pastoris cells using the method
described by Spickett et al. 2001 [28]. Shake flask cultures of 25 ml
were set up and approximately 5 ml culture harvested 48 h post-in-
duction. The culture was centrifuged at 10,000 ×g and the supernatant
discarded. The cell pellets weighed approximately 50 mg and 0.5 ml
methanol at 50 °C was added before incubating in a sonicating water
bath for 15 min. 0.5 ml chloroform was then added and the cells so-
nicated for a further 15 min. 0.5 ml of 0.88% KCl was added and the
mixture was vortexed. The cells were centrifuged at 10,000 ×g for
2 min to separate the organic and aqueous layers. The organic (lower)
layer was transferred to a fresh tube and dried under a stream of ni-
trogen gas. The lipid extracts were stored at −80 °C until analysis. For
lipid extraction from A2AR–SMALPs, approximately 50 ml of cell cul-
ture was used, and the resulting A2AR–SMALP preparation after pur-
ification according to Section 2.4 was subjected to methanol-chloro-
form extraction as described above for total lipids.
2.8. Liquid chromatography with tandem mass spectrometry (LC-MS/MS)
Phospholipid extracts of Pichia pastoris membranes were recon-
stituted in 200 μl 1:1 methanol: chloroform (v/v) and diluted (typically
1/1000) in 20% isopropyl alcohol in acetonitrile. Aliquots (10 μl) were
injected via an autosampler onto a ACE 3-SIL HILIC column
(150 × 3.1 mm, Hichrom, UK) and separated using a U3000 HPLC
system controlled by Chromeleon software (ThermoFisher, Hemel
Hempstead, UK). The HPLC was interfaced to a 5600 TripleTOF mass
spectrometer (ABSciex, Warrington, UK) via a TurboSpray® ion source.
Elution was achieved by a multi-step gradient as follows: 0–1 min held
at 5% B; 1–5 min to 8% B; 5–10 min to 15% B; 10–13 min held at 15%
B; 13–23 min to 35% B; 23–28 min held at 35% B; 28–29 min to 5% B;
29–45 min held at 5% B, where solvent A was 20% isopropyl alcohol in
acetonitrile and solvent B was 20% isopropyl alcohol in 20 mM aqueous
ammonium formate. The flow rate was set to 300 μl/min throughout.
The source temperature was set at 350 °C; the spray voltage was
5500 V; the declustering potential was set to 50 V for all scans; nitrogen
was used as the curtain gas and nebulising gas with flow rates set to
35 AU and 26 AU respectively. Survey scan MS data were acquired by
electrospray ionization in positive mode from 400 to 1200 Da in high
resolution mode for 500 ms. Information dependent data acquisition
(IDA) was used to collect MS/MS data based on following criteria: the 4
most intense ions with +1 charge and a minimum intensity of 250 cps
were chosen for analysis, using dynamic exclusion for 20 s after 2 oc-
currences and a fixed collision energy setting of 47 eV.
2.9. Molecular modelling
Models of [W246Y]A2AR and [W268Y]A2AR were built in Modeller
[29] using the A2AR with bound ZM241385 (PDB ID: 3EML) as a
template. 1000 models were generated for each mutation and scored
using the Modeller objective scoring function. The best models were
subsequently relaxed using Rosetta [30]. Ligands were docked and
scored using PLANTS under the default settings [31].
2.10. Residue numbering
The Ballesteros-Weinstein nomenclature system for family A GPCR
residues is employed throughout this article, indicated by a superscript
number [32]. This provides the unique position of each residue with
two numbers; its transmembrane helix plus its position relative to the
most conserved residue (ascribed the number 50) in that helix across all
family A GPCRs. This numbering system allows direct comparison of
residues between different GPCRs.
3. Results
3.1. Tryptophan fluorescence of A2AR-SMALP
The A2AR-SMALPs were generated using SMA (2.5% w/v) to extract
the receptors from A2AR-expressing membranes into SMALPs, followed
by purification of the A2AR-SMALPs as previously described [18]. Each
sample of purified A2AR-SMALP was tested for specific binding of the
A2AR radio-ligand [3H]ZM241385 to ensure that it was pharmacologi-
cally active. The wild-type A2AR has seven tryptophan residues but the
C-terminally truncated construct used in the current study has only six
(Supplentary Fig. 1a). Of these, Trp291.55 and Trp321.58 are at the
bottom of TM1, at the junction with the first intracellular loop (ICL1).
Trp1294.50 is in TM4. Trp1434.64 is at the junction between TM4 and
extracellular loop 2 (ECL2), Trp2466.48 is in TM6 and Trp2687.33 is at
the extracellular face of TM7 at the junction with ECL3 (Fig. 1).
The initial stage of the investigation was to determine the Trp
fluorescence spectrum of the apo A2AR-SMALP, in the absence of any
ligand (Fig. 2). The spectrum exhibited a broad peak (reflecting the
multiple Trp in the receptor) with a maximum of ~330 nm, indicating
that the Trp residues are located in relatively non-polar environments.
This is consistent with the buried positions of the Trp residues within
the receptor structure, as seen in the crystal structures of the receptor
(Fig.1). The fluorescence of ZM241385 at 330 nm is 2550 AU,< 1.5%
of that of the receptor, indicating that the changes seen in Fig. 2 are due
to the A2AR. We also determined the fluorescence spectrum of the A2AR
after solubilisation with the detergent n-dodecyl-β-D-maltopyranoside
(data not shown); it also had a single peak at approximately 330 nm,
suggesting that the overall folding of the protein was similar in the
SMALP and detergent.
3.2. Ligand-induced changes in tryptophan fluorescence
To investigate the effect on the Trp fluorescence spectrum of ligands
binding to the A2AR encapsulated in a SMALP, two ligands possessing
different pharmacological properties (efficacy) were employed; i)
ZM241385, an A2AR-selective inverse agonist which suppresses re-
ceptor activation [25] and ii) NECA, an agonist that fully activates the
receptor. Binding of ZM241385 increased the Trp fluorescence A2AR-
SMALP markedly (30%) compared to the unoccupied receptor (Fig. 2).
In contrast there was no change in the fluorescence with NECA (data
not shown). The 30% increase in the Trp fluorescence of the
ZM241385:A2AR-SMALP complex compared to the apo A2AR reveals a
ZM241385-induced conformational change in the receptor structure
upon ligand binding. Intriguingly, the increase in fluorescence intensity
was accompanied by a red shift. This is unusual as it would be expected
that an increase in intensity (interpreted as a movement of Trp residues
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into a less polar environment) should be accompanied by a corre-
sponding blue shift. However, close examination of the spectrum of the
ZM241385-bound conformation offers some insight. The apo A2AR-
SMALP spectrum shows only a single broad peak at 330 nm indicating
that the Trp residues are either in similar environments or that their
peaks are broad and overlap to a large degree. It can be seen in Fig. 2,
that ZM241385 binding induced the single peak to resolve into three
clear sub-peaks at approximately 321 nm, 335 nm and 350 nm. These
peaks are likely to represent individual Trp residues affected by the
change in local structure induced by ZM241385 binding, resulting in a
significant change in their spectral characteristics. It is therefore pos-
sible that the unusual redshift observed upon ZM241385 binding is the
net result of complex changes in the fluorescence arising from multiple
Trp transitions in the protein.
3.3. Changes in Trp fluorescence correlate with ZM241385 binding to
A2AR-SMALP
The concentration-dependence of changes in the Trp fluorescence
observed when ZM241385 bound was determined. The effect of
ZM241385 binding on the overall Trp fluorescence is presented in
Fig. 3a. This exhibits a pEC50 = 7.2 ± 0.22 (n = 3) which is com-
parable to the corresponding value for ZM241385 binding to A2AR-
SMALP (7.79 ± 0.14, n = 3) and binding to A2AR in whole mem-
branes (7.95 ± 0.45, n = 3). As the fluorescence spectrum of the
ZM241385-bound state exhibited three distinct sub-peaks of fluores-
cence (at 321 nm, 335 nm and 350 nm), the response of each of these to
increasing concentrations of ZM241385 was analysed. The ZM241385
concentration-response curves at 321 nm, 335 nm and 350 nm gave
similar pEC50 values of 6.93 ± 0.14, 7.00 ± 0.10 and 7.01 ± 0.10
respectively (Fig. 3b). This indicates that each of the putative Trp re-
sidues that correspond to these peaks are responding to the same
binding event.
3.4. Solvent accessibility of Trp residues in apo and ligand-bound states
Stern-Volmer (SV) quenching experiments were performed to
compare the solvent accessibility of the Trp residues in the unoccupied
apo A2AR-SMALP versus the ZM241385-bound state. Acrylamide was
used as the fluorescence quenching agent, as it has the advantage of
being uncharged thereby avoiding any potential charge-related pro-
blems with the polymer component of the SMALP. A full emission
spectrum was determined at each acrylamide concentration, so that an
SV constant could be calculated for the overall fluorescent species (by
producing an SV curve from an average of all data). In addition, SV
constants were also calculated for each of the Trp peaks (321 nm,
335 nm, 350 nm) resolved in the ZM241385-bound state (Fig. 4a). In all
cases, the binding of ZM241385 to the A2AR-SMALP decreased the SV
constant (Fig. 4b), indicating that the solvent accessibility of the Trp
residues in the apo A2AR decreased upon ZM241385 binding. This
agrees well with our earlier observation that the overall fluorescence
intensity of the A2AR-SMALP increased when ZM241385 occupied the
receptor (Fig. 2), indicating that the Trp residues moved to a less polar
environment.
Interestingly, there was a difference between the SV constants cal-
culated at different positions in the spectrum (corresponding to the
three peaks observed in the ZM241385-bound state. Fig. 4b). The SV
constants for 335 nm and 350 nm were very similar (3.04 and 3.16
Fig. 1. Location of the Trp residues in the A2AR.
The structure of ZM241385 (inverse agonist)-bound A2AR (yellow; PDB ID: 3EML) is aligned to the structure of the NECA (agonist)-bound A2AR (red; PDB ID: 2YDV)
with the Trp residues indicated, viewed through the plane of the membrane (panel a) and from above (panel b).
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respectively), suggesting that Trp residues generating these peaks have
similar solvent accessibilities. In contrast, the 321 nm peak has a much
lower SV value (SV = 2.60) indicating a decreased solvent exposure
compared to 335 nm and 350 nm. This latter result correlates well with
the blue-shifted nature of the 321 nm peak.
3.5. Measurement of fluorescence anisotropy changes upon ZM241385
binding
Fluorescence anisotropy can be used to determine changes in
fluorophore flexibility. Depending upon the fluorescence lifetime of the
fluorophore, this can include detecting changes in the tumbling time of
the assembly in solution, as well as changes in the motions of the
fluorophore within the context of the assembly. We have already shown
in this study that the binding of ZM241385 to the A2AR-SMALP altered
the environment and solvent accessibility of one or more of the Trp
residues. It is also likely that ZM241385 binding altered the steric
freedom of these residues in the receptor. It is however, unlikely that
the overall tumbling of the A2AR-SMALP would be affected significantly
by ZM241385 binding to the SMALP-encapsulated A2AR.
Measurements of the fluorescence anisotropy of A2AR-SMALP
showed that binding of ZM241385 produced a clear increase in aniso-
tropy (apo A2AR-SMALP, 0.1044 ± 0.0027; ZM241385-bound A2AR-
SMALP, 0.1341 ± 0.0020, values are mean ± s.e.m., n = 3,
p < .001). This indicated that the Trp residues are less mobile in the
ZM241385:A2AR-SMALP complex than in the unoccupied apo A2AR-
SMALP. Again, this agrees well with other data in this study (Figs. 2–4)
showing that Trp residues in the ZM241385-bound state are in a less
polar, less solvent-exposed and potentially more sterically-hindered,
environment.
3.6. Analysis of Trp-mutated A2AR constructs
Individual Trp residues in the A2AR were mutated to Tyr in an at-
tempt to deconvolute the contributions made to the overall fluores-
cence spectrum by at least some of the Trp residues. Trp2466.48 and
Trp2687.33 were selected for Tyr substitution as it was reasoned that
they were most likely to report on A2AR conformational changes, as
TM6 and TM7 are dynamic helices in GPCRs generally and are linked to
GPCR activation [8]. Both [W246Y]A2AR and [W268Y]A2AR were well-
expressed, although the affinity for ZM241385 for these mutant re-
ceptors was reduced by 6-fold and 27-fold, respectively ([W246Y]A2AR
Fig. 3. ZM241385-induced changes in fluorescence of A2AR-SMALP.
Panel a; the dose-dependent effect of ZM241385 binding on the overall fluor-
escence. Panel b; the dose-dependent effect of ZM241385 binding on the in-
dividual fluorescence peaks at 321 nm, 335 nm and 350 nm.
SMALP 
Sample 
Wavelength 
(nm) 
SV constant 
(M-1) 
Apo A2AR overall 3.31 
 321 3.36 
 335 3.83 
 350 3.85 
ZM:A2AR overall 2.60 
 321 2.60 
 335 3.04 
 350 3.16 
Fig. 4. Stern-Volmer quenching data.
Upper panel; quenching data for A2AR-SMALP and ZM:A2AR-SMALP. Lower
panel; calculated SV constants for overall fluorescence and for individual sub-
peaks.
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- pIC50 6.99 ± 0.46; [W268Y]A2AR - pIC50 6.36 ± 0.17; wild-type
A2AR pIC50 7.79 ± 0.14). This was not unexpected as Trp2466.48 forms
part of the binding site for ZM241385 [33] and Trp2687.33 may influ-
ence the local conformation at the extracellular face of TM7/ECL3,
controlling ligand access to the binding pocket. Despite this, it was still
possible to measure changes in the fluorescence spectrum caused by
ZM241385 binding to the mutant constructs, suggesting that the overall
structure of the protein was maintained. This was further supported by
computational molecular modelling which revealed that the predicted
structures of [W246Y]A2AR and [W268Y]A2AR were virtually super-
imposable on that of WT A2AR, with RMS deviations of< 0.01Å (Sup-
plementary Fig. 2), suggesting that there was no gross disruption of
folding.
In the absence of ZM241385, the spectrum of [W246Y]A2AR-SMALP
showed two clear peaks, one at 329 nm (like the WT A2AR-SMALP) and
a second at 315 nm (Fig. 5). Given that the protein can still bind
ZM241385, the appearance of this second peak is likely to result from
the removal of the fluorescence from Trp2466.48, probably centred close
to 320 nm, which would obscure the fluorescence at 315 nm in the WT
A2AR. The spectrum of [W268Y]A2AR in the absence of ZM241385 also
showed two peaks, again one at 329 nm (like the WT) plus a second
peak at 315 nm (Fig. 5). The relative intensities are different to those
observed for [W246Y]A2AR-SMALP but again these data are indicative
of the mutated Trp having an emission between 315 and 329 nm.
Addition of ZM241385 to both mutant receptors led to a significant
decrease in fluorescence and accompanying red shift (Fig. 5). The red
shift agreed with that seen in the WT A2AR, however the intensity
change is completely different (although a red shift is more usually seen
with an intensity decrease). This suggested that the substituted Trp
residues contributed an increase in fluorescence upon ZM241385
binding to the WT A2AR. Their substitution means that these fluores-
cence decreases were caused by one or more of the remaining Trp
residues moving to a more polar environment in response to ZM241385
binding. The corollary of this, is that both Trp2466.48 and Trp2687.33
moved into a less polar environment upon binding ZM241385.
3.7. Analysis of IAEDANS-labelled A2AR
To investigate ligand-induced conformational changes in the cyto-
plasmic face of the A2AR, a fluorescent reporter (IAEDANS) was in-
troduced at residue 6.33, located at the cytoplasmic end of TM6. A
fluorescent moiety at this locus within the receptor architecture is well-
placed to report on the dynamic changes that are known to occur at the
intracellular face of the helical bundle during receptor activation. In
particular, the large outward movement of the cytoplasmic end of TM6
away from the helical bundle that creates the binding crevice in the
receptor for G-protein docking [8]. The IAEDANS reagent used in the
current study reacted with thiol groups, so the strategy employed in-
volved introducing a Cys at residue 2316.33 followed by derivatisation
of the A231C mutant construct by IAEDANS. The A2AR used in this
study contained fourteen Cys residues (Supplementary Fig. 1b), so it
might be assumed that this would prevent such a strategy. However,
upon closer examination, it can be seen that the eight Cys residues in
the extracellular loops contribute to disulphide bonds (Cys712.69 -
Cys1595.20; Cys743.22 - Cys1464.67; Cys773.25 - Cys1665.27 and
Cys2596.61 - Cys2626.64) so will not react with IAEDANS. The remaining
six Cys residues (Cys281.54; Cys823.30; Cys1284.49; Cys1855.46;
Cys2456.47; Cys2546.56) are located in the TMs (Supplementary Fig. 1b),
so are buried to varying degrees and therefore would be only poorly
accessible to the IAEDANS. This was confirmed in control experiments
that established the fluorescence of the WT A2AR-SMALP (with
Ala2316.33) after IAEDANS labelling was identical to that of ‘empty
SMALP’ formed of lipid only and devoid of any A2AR (Supplementary
Fig. 3). Mutation of A2316.33 did not alter the binding capability of the
Fig. 5. Effect of substitution of individual Trp residues on A2AR-SMALP fluorescence.
Panel a; A2AR-SMALP and [W246Y]A2AR-SMALP in the absence of ZM241385. Panel b; A2AR-SMALP and [W268Y]A2AR-SMALP in the absence of ZM241385. Panel
c; A2AR-SMALP and [W246Y]A2AR-SMALP with ZM241385 (1 μM) bound. Panel d; A2AR-SMALP and [W268Y]A2AR-SMALP with ZM241385 (1 μM) bound.
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receptor (Supplementary Fig. 4) and following IAEDANS-labelling of
Cys2316.33, a robust fluorescent signal was detected (Fig. 6). The effect
of ligand binding on the fluorescence intensity of the IAEDANS-labelled
A2AR-SMALP was investigated. Binding of the inverse agonist
ZM241385 to A2AR-SMALP generated a marked dose-dependent in-
crease in fluorescence (Fig. 6a) with a pEC50 of 8.74 ± 0.32 (n = 3),
indicating that ZM241385 binding drove the IAEDANS to move to a
more hydrophobic environment. In contrast, the agonist NECA pro-
duced only a 9% increase in fluorescence (Fig. 6b) that was nevertheless
dose-dependent (Fig. 6c) with a pEC50 of 6.37 ± 0.21 (n = 3).
3.8. Analysis of lipid composition
To confirm that the use of SMALPs for membrane protein extraction
allows the local lipid environment to be retained, LC-MS/MS was used
to characterize the A2AR-associated phospholipids extracted from P.
pastoris membranes using SMALPs, in comparison with the total mem-
brane phospholipids (Fig. 7). The phospholipid species in SMALP ex-
tracts were identified based on the accurate mass and in some cases
additionally their fragmentation pattern, and are listed in Table 1. The
phospholipid elution profile on the HILIC column was determined by
running standard mixtures of phosphatidylethanolamine (PE), phos-
phatidylserine (PS) and phosphatidylcholine (PC), which allowed these
lipid classes to be identified in chromatograms of total membrane and
SMALP extracts (Fig. 7a and b, respectively). Although the amount of
phospholipid extracted using SMALPs was, not surprisingly, sig-
nificantly less than that obtained from total cell extracts, PE and PC
could clearly be identified (Fig. 7c and d; Fig. 7g and h). The levels of PS
were low even in total membrane extracts, and in SMALP extracts they
were essentially below the limit of detection (Fig. 7e and f). As the
phospholipid levels in SMALP extracts were low, signals from back-
ground contaminant ions in the clusters centred on m/z 758.2, 772.3
and 829.5 are prominent, especially in Fig. 7f. Overall, whilst there was
some evidence that the ratio of poly-unsaturated to mono-unsaturated
PC species was slightly higher in SMALP extracts (e.g. m/z 758.5 vs
760.5, m/z 786.5 vs 788.5 and higher relative intensity of m/z 808.5),
the profile of SMALP-extracted A2AR-associated phospholipid appeared
to be generally similar to the total membrane.
4. Discussion
To fully understand the structure and function of a membrane
protein it is necessary to extract it from the lipid bilayer for purification.
This usually requires detergents to disrupt the membrane but generally
leads to protein instability as the lipids of the bilayer are stripped away
[34]. In recent years there has been a large increase in the use of SMA to
Fig. 6. Ligand-induced changes in IAEDANS fluorescence.
The effect on fluorescence intensity of exposure to ZM241385 (10−10 M – 10−5 M; panel a) or NECA (10−7 M – 10−5 M; panel b) at the concentrations indicated was
determined for A2AR-SMALP labelled with IAEDANS at residue-231. Panel c; Concentration-response curves for the fluorescence intensity changes induced by
ZM241385 or NECA.
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Fig. 7. Comparison of the phospholipid profiles of bulk membrane lipids, and SMALP-extracted lipids, from P. pastoris.
Different classes of phospholipids were separated by HILIC and analysed by electrospray MS in positive ion mode. Data were summed across each of the elution
regions in the TICs shown in panels a and b to generate the spectra for each class shown in the panels c-h. The y-axis shows the % intensity in counts per second (cps)
normalized to 100% for the most intense peak in the spectrum across the mass range analysed. For each class of phospholipid, the y-axes of the bulk membrane and
SMALP spectra are linked to allow a relative comparison of intensity. Note that phospholipid signals give m/z values with decimal 0.5 and signals with m/z values
ending 0.2 or 0.3 are background contaminants. Identifications of the individual phospholipids are given in Table 1.
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extract a wide range of membrane proteins encapsulated in SMALPs.
This preserves the native membrane environment of the protein albeit
on a nanoscale, and improves stability. We established previously that
the A2AR could be purified encapsulated in a SMALP with retention of
wild-type ligand binding capability [18]. It is well-established that
GPCRs can form dimers and that heterodimerization can modulate
GPCR signalling. Such interaction is maintained within a SMALP, as a
tetrameric (2 + 2) complex of ghrelin receptor (GHSR) and dopamine
receptor (D2R), isolated by SMALP-solubilisation of reconstituted lipid
vesicles, retained GHSR modulation of D2R signalling [35]. The aim of
the current study was to investigate the conformational changes in-
duced by binding ligands to the A2AR when it is encapsulated in a
SMALP.
We were able to demonstrate that SMALP-encapsulated A2AR con-
tained phospholipids typical of the plasma membrane, including PCs
and PEs. It has been reported previously that interactions of some
GPCRs, e.g. neurotensin receptor 1, with G-proteins are dependent on a
native-like lipid environment containing PEs [36], although the β2-
adrenergic receptor showed higher activity in the presence of phos-
phatidylglycerols (PGs) than PEs [10]. Other GPCRs have been reported
to require cholesterol [11,37] and the active state of the A2AR is sta-
bilised by the binding of phosphatidylinositol 4,5-bisphosphate [12].
Although the plasma membrane of P. pastoris differs from that of
mammalian cells, notably in substitution of cholesterol by ergosterol,
the major classes of phospholipids are similar and the A2AR was phar-
macologically active. Phosphatidylinositols and inositol ceramides are
minor, though important, membrane components and in the present
study were below the detection limit of the method; hence it is not
possible to comment on their contribution to the activity observed.
However, proteins within SMALPs can be exchanged into detergent or
amphipol [38] or into vesicles of alternative phospholipid composition
[39] and SMALP phospholipids can also be exchanged [40], which in
the future offers alternative approaches for improving GPCR activity
following isolation in SMALPs.
In its native membrane, the A2AR exhibits considerable constitutive
activity in the absence of agonist, which can account for over 50% of
the agonist-stimulated activity [23] and this can be reduced by inverse
agonists such as ZM241385 [41]. It is well-established that activation of
GPCRs involves conformational changes that are conserved throughout
the receptor family [8]. In particular, there is a large (10 - 14 Å)
movement of the cytoplasmic end of TM6 away from the helical bundle
that opens a cleft in the cytoplasmic face of the receptor for G-protein
docking [42]. The fluorescent moiety IAEDANS introduced at residue
2316.33, at the cytoplasmic face of TM6, is therefore well-placed to re-
port on the dynamic changes that occur on the intracellular face of the
A2AR during activation. Indeed, a fluorescent reporter located at the
corresponding locus in the β2-AR (A2716,33) was used previously to
monitor activation of the β2-AR [43].
The IAEDANS data in the current study show that SMALP-solubi-
lised A2AR retains substantial elements of the constitutively active
conformation of A2AR existing in the native membrane environment.
Binding of ZM241385 caused a substantial dose-dependent increase in
fluorescence emission. The simplest explanation of this is that the
IAEDANS probe moved into a more hydrophobic environment. This is
what would be expected if the cytoplasmic end of TM6, in the absence
of the inverse agonist, was part of an open conformation to accom-
modate binding of Gsα and binding of ZM241385 closed the Gsα binding
crevice. Such conformational transitions and movement of TM6 be-
tween active and inactive A2AR are consistent with the corresponding
crystal structures [44]. Kinetic data indicate that the binding of
ZM241385 is biphasic, consistent with conformational changes of the
receptor [45]. In contrast, the agonist NECA caused very little change in
IAEDANS fluorescence emission.
The fluorescence of endogenous Trp residues is a powerful tech-
nique to study the conformation of native proteins. Trp are important
residues in their own right. Their large size, coupled with the ability to
take part in hydrophobic and columbic interactions means that they
often act as switches or pivots during conformational changes. There
are a number of highly conserved Trp residues in GPCRs, including
Trp6.48 in TM6, referred to as the “rotamer toggle switch” [46]. An
Table 1
Phospholipid species detected by high resolution LC-MS/MS in SMALP-extracted P. pastoris samples.
Experimental m/z Retention time (min) Molecular formula Calculated m/z Error in ppm Phospholipid species
Glycerophosphocholines ([MH]+)
732.5528 19.36 C40H79NO8P 732.5543 2.1 GPC (32:1)
744.5530 19.27 C41H79NO8P 744.5543 1.8 GPC (16:1/17:1)a
746.5673 19.31 C41H81NO8P 746.5700 3.6 GPC (33:1)
754.5373 19.27 C42H77NO8P 754.5387 1.8 GPC (34:4)
756.5529 19.24 C42H79NO8P 756.5543 1.9 GPC (34:3)
758.5667 19.25 C42H81NO8P 758.5694 3.7 GPC (16:1/18:1)a
760.5828 19.27 C42H83NO8P 760.5851 3.7 GPC (34:1)
768.5510 19.22 C43H79NO8P 768.5538 3.6 GPC (18:3/17:1)a
770.5667 19.20 C43H81NO8P 770.5694 3.5 GPC (35:3)
772.5844 19.20 C43H83NO8P 772.5851 1.6 GPC (18:1/17:1)a
780.5526 19.22 C44H79NO8P 780.5538 2.2 GPC (18:3/18:2)a
782.5667 19.18 C44H81NO8P 782.5695 3.6 GPC (18:2/18:2)a
784.5823 19.14 C44H83NO8P 784.5851 3.3 GPC (36:3)
786.5979 19.14 C44H85NO8P 786.6008 3.7 GPC (18:1/18:1)a
Glycerophosphoethanolamines ([MH]+)
690.5063 12.43 C37H73NO8P 690.5074 1.6 GPE 32:1)
704.5217 12.54 C38H75NO8P 704.5230 1.9 GPE (33:1)
716.5220 12.73 C39H75NO8P 716.5230 1.4 GPE (34:2)
718.5370 12.68 C39H75NO8P 718.5387 2.3 GPE (34:1)
738.5059 12.47 C41H73NO8P 738.5074 2.0 GPE (36:5)
742.5369 12.67 C41H77NO8P 742.5387 2.4 GPE (36:3)
744.5528 12.70 C41H79NO8P 744.5543 2.1 GPE (18:0/18:2)a
764.5201 12.65 C43H75NO8P 764.5230 3.8 GPE (38:6)
766.5348 12.65 C43H77NO8P 766.5387 5.1 GPE (38:5)
Glycerophosphoserines ([MH]+)
762.526 14.12 C40H77NO10P 762.5285 3.3 GPS (34:1)
For other phospholipid species the total fatty acyl chain length: double bonds are given.
a Fatty acyl chain composition determined by observation of fatty acyl ions in MS/MS spectra.
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agonist-induced shift of this conserved Trp6.48 promotes the outward
tilt of the intracellular part of TM6 required for G-protein coupling
described above. It has already been noted that IAEDANS fluorescence
emission was affected by ZM241385 binding and ZM241385 also
caused changes in the environments of the Trp residues in the SMALP-
solubilised A2AR. The agonist NECA however, did not affect the Trp
fluorescence. The predominant change upon ZM241385 binding in-
volved an increase in fluorescence emission and the appearance of three
distinct peaks in the fluorescence spectrum at 321 nm, 335 nm and
350 nm. Interestingly, two of these peaks (321 nm, 335 nm) have
wavelengths that are not far from those observed in the spectra of the
unliganded mutant constructs [W2466.48Y]A2AR-SMALP and
[W2687.33Y]A2AR-SMALP (peaks at 315 nm and 329 nm). This confirms
that in each conformation there are Trp residues present that maintain
similar spectroscopy.
Analysis of the Trp/Tyr substitution mutants suggests that
Trp2466.48 and Trp2687.33 are responsible for the increase in the
fluorescence emission observed when ZM241385 binds to the WT.
These Trp residues are not located near to the cytoplasmic face of the
A2AR and thus report on different regions from that measured by the
IAEDANS at residue 2316.33. For Trp2466.48 in TM6, two mechanisms
may contribute to the change in fluorescence. The antagonist may
trigger a conformational change in the A2AR-SMALP that moves the
residue to a more hydrophobic environment. However, binding of
ZM241385 could also reduce the solvent accessibility of Trp2466.48 as it
is located in the ZM241385 binding pocket where it forms a hydro-
phobic contact with the furan ring of ZM241385 [33], along with ad-
jacent residues [47]. Both mechanisms could decrease the rotation of
the residue, consistent with the measured reduction in anisotropy and
hence fluorophore mobility. However, as NECA also binds close to
Trp2646.48 and yet does not change Trp fluorescence, it seems a con-
formational change in the receptor is the most likely explanation.
Our observation that the inverse agonist ZM241385, which inhibits
activation, caused the ‘rotamer toggle switch’ Trp2466.48 of the A2AR-
SMALP to move to a more hydrophobic environment is the exact op-
posite effect to that accompanying photo-activation of rhodopsin.
Photo-activation of rhodopsin causes the corresponding residue
(Trp2656.48) to transition to a more hydrophilic environment [48].
These two observations are consistent with respect to linking the nature
of the Trp6.48 environment and the activation state of the GPCR.
Trp2687.33 is at the extracellular face of TM7, on the boundary
between the membrane and the extracellular aqueous medium.
ZM241385 binds in an extended conformation perpendicular to the
plane of the membrane. Nevertheless, the changes seen here are un-
likely to be due to direct contact with ZM241385 with Trp2687.33, so
probably reflect changes in receptor conformation, although crystal
structures reveal that ZM241385 does make hydrophobic interactions
with other residues at the extracellular face of TM7 (L2677.32 and
M2707.35) [49,50]. There is also evidence for movement of ECL3 during
activation of the A2AR with molecular dynamic studies suggesting that
compaction of the extracellular domain of the A2AR underlies the po-
sitive allosteric effects of divalent cations as they bridge across acidic
residues in ECLs [51]. Even a small movement of the indole head-group
of Trp2687.33 towards the membrane, induced by ZM241385 binding,
would be expected to significantly reduce its polarity and could po-
tentially reduce its mobility. Another factor that could be relevant to
changes in the environment of residues within the TM helical bundle
are the ordered water molecules within the receptor structure [49,52].
Whilst the changes seen with Trp2466.48 and Trp2687.33 dominate the
spectrum, their substitution by Tyr unmasks changes due to other Trp
residues having greater solvent accessibility. Caution is needed in in-
terpreting this as the Trp/Tyr mutations have some effect on ZM242385
binding. Nevertheless, despite this caveat, it is at least plausible that in
the WT receptor some of the Trp residues on, or close to, the in-
tracellular or extracellular loops will have greater solvent exposure
following antagonist binding, thus experiencing an increase in polarity.
In conclusion, the SMALP-solubilised A2AR adopted a conformation
that retained the native constitutive activity. Using fluorescence
changes from endogenous Trp residues and an introduced IAEDANS, we
established that the receptor was able to undergo ligand-induced con-
formational changes with the SMALP environment in response to
binding the inverse agonist ZM241385. In contrast, the SMALP-en-
capsulated A2AR exhibited little conformational change in response to
the full agonist NECA.
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